实力铸就丨昭衍新药助力四款药物获批上市!

昭衍JOINN
30 May

昭衍助力在生物医药领域,每一次新药的获批上市都意味着为患者带来了新的希望和曙光。近日,中国国家药品监督管理局(NMPA)传来喜讯,复星医药的芦沃美替尼片、嘉和药业的盐酸来罗西利片、特宝生物的怡培生长激素注射液以及迈威生物全资子公司泰康生物的阿格司亭α正式获批上市。而在这些创新药物的研发进程中,昭衍新药凭借其专业的服务和卓越的技术,为它们的成功获批发挥了重要的作用。在四款创新药物的临床前研发阶段,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10